Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by Oric Pharmaceuticals, Inc. on June 11, 2025. The filing details the voting results for director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.
Material Changes and Voting Results
As of the record date (April 16, 2025), there were 71,085,080 shares of common stock outstanding. A total of 58,306,933 shares (82.02%) were represented at the meeting.
Proposal 1: Election of Directors
Two Class II directors were elected to serve until the 2028 annual meeting:
- Steven L. Hoerter: 48,495,296 votes For; 410,879 votes Withheld; 9,400,758 Broker Non-Votes.
- Angie You, Ph.D.: 39,959,137 votes For; 8,947,038 votes Withheld; 9,400,758 Broker Non-Votes.
Proposal 2: Ratification of Auditor
Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- For: 58,252,180
- Against: 44,897
- Abstain: 9,856
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (71,085,080) and the percentage of shares represented at the meeting (82.02%).
- Confirm the election of Steven L. Hoerter and Angie You, Ph.D., as Class II directors.
- Note the significant number of broker non-votes (9,400,758) in the director election, which did not affect the outcome but indicates shares held in street name where brokers lacked discretionary authority.
- Confirm the ratification of KPMG LLP as the auditor for the 2025 fiscal year.